Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors [Phase 1]
This clinical trial update describes a Phase 1 study of PF-08046049/SGN-BB228 in advanced melanoma and other solid tumors, with the conditio…
-
CLINICAL_TRIALS trial_result · 2026-04-20Clinical Trial Update: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer [Phase 3]
Phase 3 trial evaluating Olomorasib (LY3537982) in combination with standard of care for KRAS G12C-mutant non-small cell lung cancer is curr…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies [Phase 1]
Phase 1 trial evaluating CTX-471 as a monotherapy or in combination with pembrolizumab in patients who progressed after PD-1/PD-L1 inhibitor…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies [Phase 1]
Phase 1 trial of AUR106 in relapsed advanced malignancies has been terminated; the document provides a status update on this study.
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study [Phase 2]
Phase 2 trial assessing pembrolizumab for prevention of lung cancer in patients with Stage I-II non-small cell lung cancer or high-risk pulm…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) [Phase 1]
Phase 1 trial MK-2870-008 evaluating sacituzumab govitecan as a single agent and in combination with pembrolizumab for advanced solid tumors…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) [Phase 1, Phase 2]
LIBRETTO-001 is a Phase 1/2 trial of selpercatinib in RET fusion–positive advanced solid tumors, including non-small cell lung cancer and me…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer [Phase 1]
Phase 1 clinical trial update evaluating osimertinib in combination with alisertib or sapanisertib for osimertinib-resistant EGFR-mutant sta…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors [Phase 1]
Novartis' Phase 1 dose-finding trial of TNO155 in adults with advanced solid tumors has been terminated. No efficacy results are provided in…
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer [Phase 3]
A Phase 3 trial evaluating nogapendekin alfa inbakicept for advanced non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: ITIL-306 in Advanced Solid Tumors [Phase 1]
A Phase 1 trial of ITIL-306 in advanced solid tumors sponsored by Instil Bio has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-15Clinical Trial Update: A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer [Phase 3]
This update notes the completion of a Phase 3 multinational, randomized, open-label study evaluating custirsen in patients with advanced or …
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) [Phase 2]
A Phase 2 trial evaluating ablative stereotactic radiotherapy combined with durvalumab (MEDI4736) in Stage I non-small cell lung cancer has …
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer [Phase 1]
Phase 1 trial evaluating cilengitide in combination with radiochemotherapy for locally advanced non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
A completed clinical trial update reporting the real-world outcomes of first-line nivolumab plus ipilimumab with chemotherapy for non-small …
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) [Phase 1, Phase 2]
Bayer's BAY2927088 is being investigated in a first-in-human Phase 1/2 study for adults with advanced non-small cell lung cancer harboring E…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
A completed post-marketing surveillance study in Japan evaluating durvalumab for non-small cell lung cancer under the Imfinzi/Imjudo brands.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Study of Outcomes of Radiofrequency Ablation of Lung Tumors
This clinical trial update notes that the study on outcomes of radiofrequency ablation for lung tumors has been suspended.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: GEN1047 for Solid Tumors - First in Human (FIH) Trial [Phase 1, Phase 2]
Genmab's GEN1047 first-in-human Phase 1/2 trial in solid tumors has been terminated, with indications including breast cancer, endometrial c…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer [Phase 1, Phase 2]
This clinical trial update outlines a Phase 1/Phase 2 study evaluating the combination of amivantamab and docetaxel in participants with met…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
This clinical trial update discusses the risk of chemotherapy toxicity in older patients with hematologic malignancies or non-small cell lun…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
A completed Travera Inc trial evaluating TraveraRTGx and a tumor-cell biomarker intended to guide rapid therapy decisions across multiple ca…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer [Phase 1, Phase 2]
INTENSE is a Phase I/II study of inhomogeneous targeted dose escalation in non-small cell lung cancer. The trial has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
This is a Phase 1/2 clinical trial evaluating BMS-986340 as monotherapy and in combination with nivolumab or docetaxel across several advanc…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung [Phase 2]
Phase 2 trial update on a combination of a PCSK9 inhibitor and a PD-1 inhibitor for metastatic non-small cell lung cancer that is refractory…